A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation
Brain metastases (BMs) are frequently occurred in lung adenocarcinoma with driver mutation. There is a need to explore multi-discipline treatments and prognostic factors in those patients with most frequent driver mutations: EGFR mutation and ALK fusion. In the retrospective study, different therapies and prognostic factors were compared between EGFR and ALK-driven lung adenocarcinoma with BMs. 516 patients with EGFR mutation and 76 with ALK fusion were screened for this study, 303 (58.7%) and 34 (44.7%) had BM respectively. In multivariate analyses, the pretreatment factors including delayed BMs and asymptomatic BMs, treatment strategies including the first-generation tyrosine kinase inhibitor (TKI) and cranial radiotherapy (RT) treatment, were associated with much better OS in EGFR mutation patients. Moreover, we found EGFR-mutation patients receiving erlotinib would achieve better survival than those receiving gefitinib (P = 0.032). However, BM patients with ALK fusion treated by only the first generation TKI (HR = 0.23, P = 0.036) or cranial RT (HR = 0.12, P = 0.003), had better OS. After balancing of baseline characteristics of the two groups, there was no significant difference in the survival between BM patients with EGFR mutation and ALK fusion. And only cranial RT was associated with better survival in those patients (HR = 0.52, P < 0.001). In the BM patients of lung adenocarcinoma with driver mutation, TKI underlie the therapy strategies, but cranial RT still plays an important role while receiving the first generation TKI.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Clinical & experimental metastasis - 37(2020), 3 vom: 30. Juni, Seite 391-399 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Haihong [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.09.2020 Date Revised 21.09.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10585-020-10026-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309399009 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309399009 | ||
| 003 | DE-627 | ||
| 005 | 20231225133826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10585-020-10026-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1031.xml |
| 035 | |a (DE-627)NLM309399009 | ||
| 035 | |a (NLM)32356218 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Haihong |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.09.2020 | ||
| 500 | |a Date Revised 21.09.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Brain metastases (BMs) are frequently occurred in lung adenocarcinoma with driver mutation. There is a need to explore multi-discipline treatments and prognostic factors in those patients with most frequent driver mutations: EGFR mutation and ALK fusion. In the retrospective study, different therapies and prognostic factors were compared between EGFR and ALK-driven lung adenocarcinoma with BMs. 516 patients with EGFR mutation and 76 with ALK fusion were screened for this study, 303 (58.7%) and 34 (44.7%) had BM respectively. In multivariate analyses, the pretreatment factors including delayed BMs and asymptomatic BMs, treatment strategies including the first-generation tyrosine kinase inhibitor (TKI) and cranial radiotherapy (RT) treatment, were associated with much better OS in EGFR mutation patients. Moreover, we found EGFR-mutation patients receiving erlotinib would achieve better survival than those receiving gefitinib (P = 0.032). However, BM patients with ALK fusion treated by only the first generation TKI (HR = 0.23, P = 0.036) or cranial RT (HR = 0.12, P = 0.003), had better OS. After balancing of baseline characteristics of the two groups, there was no significant difference in the survival between BM patients with EGFR mutation and ALK fusion. And only cranial RT was associated with better survival in those patients (HR = 0.52, P < 0.001). In the BM patients of lung adenocarcinoma with driver mutation, TKI underlie the therapy strategies, but cranial RT still plays an important role while receiving the first generation TKI | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ALK | |
| 650 | 4 | |a Brain metastases | |
| 650 | 4 | |a EGFR | |
| 650 | 4 | |a Lung adenocarcinoma | |
| 650 | 4 | |a Therapies | |
| 650 | 7 | |a EML4-ALK fusion protein, human |2 NLM | |
| 650 | 7 | |a Oncogene Proteins, Fusion |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Erlotinib Hydrochloride |2 NLM | |
| 650 | 7 | |a DA87705X9K |2 NLM | |
| 650 | 7 | |a EGFR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Gefitinib |2 NLM | |
| 650 | 7 | |a S65743JHBS |2 NLM | |
| 700 | 1 | |a He, Dongyun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Fengnan |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Qiuhua |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Zixian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical & experimental metastasis |d 1993 |g 37(2020), 3 vom: 30. Juni, Seite 391-399 |w (DE-627)NLM012922307 |x 1573-7276 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g number:3 |g day:30 |g month:06 |g pages:391-399 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10585-020-10026-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2020 |e 3 |b 30 |c 06 |h 391-399 | ||